1. Home
  2. AERO vs URGN Comparison

AERO vs URGN Comparison

Compare AERO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AERO

Grupo Aeromexico S.A.B.

N/A

Current Price

$14.56

Market Cap

2.3B

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$43.39

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AERO
URGN
Founded
1934
2004
Country
Mexico
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
AERO
URGN
Price
$14.56
$43.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$28.57
$29.29
AVG Volume (30 Days)
295.1K
985.0K
Earning Date
04-21-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$11.85
$129.09
Revenue Next Year
$4.57
$70.96
P/E Ratio
$7.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.26
$15.86
52 Week High
$23.05
$50.81

Technical Indicators

Market Signals
Indicator
AERO
URGN
Relative Strength Index (RSI) 42.99 45.28
Support Level $13.15 $18.25
Resistance Level $16.84 $43.93
Average True Range (ATR) 0.68 1.82
MACD 0.01 -0.90
Stochastic Oscillator 43.85 14.81

Price Performance

Historical Comparison
AERO
URGN

About AERO Grupo Aeromexico S.A.B.

Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: